CompletedNCT01724476
Folate and Vitamin B12 Added to Treatment for Schizophrenia in Ethiopia
About this title
Read the official source —Medication studyAges 18–65Ethiopia
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Addis AbabaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: December 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 200
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Ethiopia
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01724476
- Official title
Show the full official title
A Placebo-Controlled Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia
Get this study by email
Recruitment & locations
CompletedAddis Ababa
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including folate with B12 and placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
